72 related articles for article (PubMed ID: 23515289)
1. Investigating new therapeutic strategies targeting hyperinsulinemia's mitogenic effects in a female mouse breast cancer model.
Rostoker R; Bitton-Worms K; Caspi A; Shen-Orr Z; LeRoith D
Endocrinology; 2013 May; 154(5):1701-10. PubMed ID: 23515289
[TBL] [Abstract][Full Text] [Related]
2. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes.
Ferguson RD; Novosyadlyy R; Fierz Y; Alikhani N; Sun H; Yakar S; Leroith D
Breast Cancer Res; 2012 Jan; 14(1):R8. PubMed ID: 22226054
[TBL] [Abstract][Full Text] [Related]
3. Type I insulin-like growth factor receptor induces pulmonary tumorigenesis.
Linnerth NM; Siwicky MD; Campbell CI; Watson KL; Petrik JJ; Whitsett JA; Moorehead RA
Neoplasia; 2009 Jul; 11(7):672-82. PubMed ID: 19568412
[TBL] [Abstract][Full Text] [Related]
4. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Shaw AT; Gandhi L; Gadgeel S; Riely GJ; Cetnar J; West H; Camidge DR; Socinski MA; Chiappori A; Mekhail T; Chao BH; Borghaei H; Gold KA; Zeaiter A; Bordogna W; Balas B; Puig O; Henschel V; Ou SI;
Lancet Oncol; 2016 Feb; 17(2):234-242. PubMed ID: 26708155
[TBL] [Abstract][Full Text] [Related]
5. Highly specific role of the insulin receptor in breast cancer progression.
Rostoker R; Abelson S; Bitton-Worms K; Genkin I; Ben-Shmuel S; Dakwar M; Orr ZS; Caspi A; Tzukerman M; LeRoith D
Endocr Relat Cancer; 2015 Apr; 22(2):145-57. PubMed ID: 25694511
[TBL] [Abstract][Full Text] [Related]
6. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
Gadgeel SM; Shaw AT; Govindan R; Gandhi L; Socinski MA; Camidge DR; De Petris L; Kim DW; Chiappori A; Moro-Sibilot DL; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; Yang JC; Han JY; Bordogna W; Golding S; Zeaiter A; Ou SI
J Clin Oncol; 2016 Dec; 34(34):4079-4085. PubMed ID: 27863201
[TBL] [Abstract][Full Text] [Related]
7. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.
Yang JC; Ou SI; De Petris L; Gadgeel S; Gandhi L; Kim DW; Barlesi F; Govindan R; Dingemans AC; Crino L; Lena H; Popat S; Ahn JS; Dansin E; Golding S; Bordogna W; Balas B; Morcos PN; Zeaiter A; Shaw AT
J Thorac Oncol; 2017 Oct; 12(10):1552-1560. PubMed ID: 28689043
[TBL] [Abstract][Full Text] [Related]
8. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
9. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
Ou SH; Ahn JS; De Petris L; Govindan R; Yang JC; Hughes B; Lena H; Moro-Sibilot D; Bearz A; Ramirez SV; Mekhail T; Spira A; Bordogna W; Balas B; Morcos PN; Monnet A; Zeaiter A; Kim DW
J Clin Oncol; 2016 Mar; 34(7):661-8. PubMed ID: 26598747
[TBL] [Abstract][Full Text] [Related]
10. Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor.
Gallagher EJ; Alikhani N; Tobin-Hess A; Blank J; Buffin NJ; Zelenko Z; Tennagels N; Werner U; LeRoith D
Diabetes; 2013 Oct; 62(10):3553-60. PubMed ID: 23835331
[TBL] [Abstract][Full Text] [Related]
11. IGF-1 Stimulates Glycolytic ATP Production in MCF-7L Cells.
Rajoria B; Zhang X; Yee D
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373357
[TBL] [Abstract][Full Text] [Related]
12. Potential Therapies Targeting the Metabolic Reprogramming of Diabetes-Associated Breast Cancer.
Shum HCE; Wu K; Vadgama J; Wu Y
J Pers Med; 2023 Jan; 13(1):. PubMed ID: 36675817
[TBL] [Abstract][Full Text] [Related]
13. Systemic Administration of Insulin Receptor Antagonist Results in Endothelial and Perivascular Adipose Tissue Dysfunction in Mice.
Proniewski B; Bar A; Kieronska-Rudek A; Suraj-Prażmowska J; Buczek E; Czamara K; Majka Z; Czyzynska-Cichon I; Kwiatkowski G; Matyjaszczyk-Gwarda K; Chlopicki S
Cells; 2021 Jun; 10(6):. PubMed ID: 34207844
[TBL] [Abstract][Full Text] [Related]
14. Hyperinsulinemia in Obesity, Inflammation, and Cancer.
Zhang AMY; Wellberg EA; Kopp JL; Johnson JD
Diabetes Metab J; 2021 May; 45(3):285-311. PubMed ID: 33775061
[TBL] [Abstract][Full Text] [Related]
15. Disrupting Insulin and IGF Receptor Function in Cancer.
Cao J; Yee D
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33429867
[TBL] [Abstract][Full Text] [Related]
16. Hyperinsulinaemia in cancer.
Gallagher EJ; LeRoith D
Nat Rev Cancer; 2020 Nov; 20(11):629-644. PubMed ID: 32908223
[TBL] [Abstract][Full Text] [Related]
17. Effects of Propolis Extract and Propolis-Derived Compounds on Obesity and Diabetes: Knowledge from Cellular and Animal Models.
Kitamura H
Molecules; 2019 Dec; 24(23):. PubMed ID: 31805752
[TBL] [Abstract][Full Text] [Related]
18. Diabetes, Obesity, and Breast Cancer.
Kang C; LeRoith D; Gallagher EJ
Endocrinology; 2018 Nov; 159(11):3801-3812. PubMed ID: 30215698
[TBL] [Abstract][Full Text] [Related]
19. Revisiting the IGF-1R as a breast cancer target.
Ekyalongo RC; Yee D
NPJ Precis Oncol; 2017; 1():. PubMed ID: 29152592
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response.
Aiken R; Axelson M; Harmenberg J; Klockare M; Larsson O; Wassberg C
Oncotarget; 2017 Oct; 8(46):81501-81510. PubMed ID: 29113409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
